Grants per year
Personal profile
Research Interests
Dr Simuni joined the faculty of the Northwestern University Feinberg school of Medicine in 2000 to build and lead a multidisciplinary movement disorders center that is recognized by the National Parkinson’s Foundation as a Center of Excellence and serves as a training model in the region. Her research interests are focused on development of disease modifying ( neuroprotective ) interventions in Parkinson’s disease (PD). She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological and surgical management of PD. As the Principal Investigator of the multicenter Parkinson Study Group (PSG) Phase II study of isradipine as potential disease modifying agent in early PD (STEADY PD) and more recently NET PD FS-Zone studies as well as a member of the Steering Committees on a number of national studies including PPMI, she has developed expertise in design and coordination of multicenter studies. She is actively involved with the PSG where she is an active member of three PSG working groups and Chair of the Classic Motor group. She serves on the Steering Committees for the National Parkinson Foundation.
Certifications and Licenses
| Neurology |
Training Experience
| 1994 | Residency, Temple University Hospital |
| 1995 | Fellowship, Temple University Hospital |
Education/Academic qualification
MD, Leningrad Medical School
… → 1985
Research interests
- Clinical Trial Methodology
- Drug Discovery
- Movement Control
Fingerprint Dive into the research topics where Tatyana Simuni is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 3 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants
Research Education Program for Trainees in Neurology
National Institute of Neurological Disorders and Stroke
7/1/20 → 6/30/25
Project: Research project
Research Output
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study
Parkinson's Progression Markers Initiative Investigators, May 1 2020, In : Movement Disorders. 35, 5, p. 833-844 12 p.Research output: Contribution to journal › Article
Open Access
1
Scopus
citations
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
PPMI Investigators, Jan 2020, In : The Lancet Neurology. 19, 1, p. 71-80 10 p.Research output: Contribution to journal › Article
3
Scopus
citations
Clinical Trial Highlights - GLP-1 agonists
McFarthing, K., Larson, D. & Simuni, T., Jan 1 2020, In : Journal of Parkinson's disease. 10, 2, p. 355-368 14 p.Research output: Contribution to journal › Article
Open Access
Clinical Trial Highlights-Infusion Therapies
Prakash, N., McFarthing, K. & Simuni, T., Jan 1 2020, In : Journal of Parkinson's disease. 10, 1, p. 5-17 13 p.Research output: Contribution to journal › Article
Open Access
1
Scopus
citations
Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists (Genetics in Medicine, (2019), 10.1038/s41436-019-0684-x)
Alcalay, R. N., Kehoe, C., Shorr, E., Battista, R., Hall, A., Simuni, T., Marder, K., Wills, A. M., Naito, A., Beck, J. C., Schwarzschild, M. A. & Nance, M., Feb 1 2020, In : Genetics in Medicine. 22, 2, 1 p.Research output: Contribution to journal › Comment/debate
Open Access